Detected ·
Cloverleaf Bio
$33M—
Cloverleaf Bio, a biotech developing a new class of cancer therapeutics based on RNA modification research from Yale, raised a $33M oversubscribed seed round with participation from Draper Associates, AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund.
- Website
- cloverleafbio.com
- linkedin.com/company/98047595
- Amount
- $33 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-14 12:16:48 UTC
- Signal ID
- 108baf95-9b8f-4043-97a5-11615a952c3b
As the API returns it
{
"id": "108baf95-9b8f-4043-97a5-11615a952c3b",
"created_at": "2026-10-14T12:16:48.667990Z",
"company_name": "Cloverleaf Bio",
"company_website_url": "cloverleafbio.com",
"company_linkedin_url": "https://www.linkedin.com/company/98047595",
"event_type": "funding",
"funding_amount": 33000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Cloverleaf Bio, a biotech developing a new class of cancer therapeutics based on RNA modification research from Yale, raised a $33M oversubscribed seed round with participation from Draper Associates, AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund.*"
}